AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01613846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib+Sorafenib
Description: Pazopanib (first-line) followed by Sorafenib (second-line)
Study NCT02980861 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic total gastrectomy
Description: When the participants with advanced proximal gastric cancer are randomized in the laparoscopic totalgastrectomy (LATG) group, they will received LTG with spleen-preserving splenic hilum lymph nodes dissection.
Study NCT02980861 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open total gastrectomy
Description: When the participants with advanced proximal gastric cancer are randomized in the open total gastrectomy(OTG) group, they will received OTG with spleen-preserving splenic hilum lymph nodes dissection.
Study NCT01667419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: 4 tablets of vemurafenib 240 mg each (total 960 mg) were administered orally as per the schedule specified in the respective arm.
Study NCT01667419 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to vemurafenib were administered orally as per the schedule specified in the respective arm.
Study NCT02663544 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Limited dairy diet
Description: Consumption of no dairy foods other than 3 servings per week of nonfat milk for 12 weeks
Study NCT02663544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-fat dairy diet
Description: Consumption of 3.3 servings per day of low-fat milk, yogurt, and cheese for 12 weeks
Study NCT02663544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Full-fat dairy diet
Description: Consumption of 3.3 servings per day of full-fat milk, yogurt, and cheese for 12 weeks
Study NCT05377801 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-dimensional fall prevention intervention program for 12 weeks
Description: The intervention group of this study is a multi-dimensional intervention conducted by nursing students over a 12-week period, consisting of four parts: individualized balance and strength training, vision screening, drug evaluation, home risk assessment and home repair and transformation. These components were carried out through a combination of personal home visits and telephone interviews.
Study NCT00097656 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multi-center, randomized, controled periodontal therapy
Description: periodontal therapy
Study NCT01814709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0032
Description: Oral doses of GDC-0032
Study NCT01814709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Oral doses of Itraconazole
Study NCT01814709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Oral doses of Rifampin
Study NCT03641404 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ergothioneine
Description: Ergothioneine is naturally occurring thiol compound obtained solely from diet in humans. Ergothioneine is widely reported to be a natural antioxidant and anti-inflammatory compound. In addition we hypothesize that this compound will be beneficial in improving cognition.
Study NCT03641404 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo. Study control (99% microcrystalline cellulose)
Study NCT02757716 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: Every patient who undergo surgery will fill out a questionnaire containing validated scales concerning food, alcohol, nicotine, internet and exercise and drug addiction prior, 6 months and 24 months after surgery.
Study NCT03472261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: Dysport
Study NCT03472261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Dysport
Study NCT03472261 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper extremity orthoses
Description: Twister
Study NCT03472261 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise program
Description: Specific exercises for pronation deformity
Study NCT03472261 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home exercise program
Description: Specific exercises for pronation deformity
Study NCT00748904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: 400 mg orally
Study NCT00748904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose
Description: 20 grams titrate to 2-3 bowel movements in one day
Study NCT00673530 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: evidence based clinical nutrition concept
Description: The evidence based nutrition concept comprise a routine malnutrition screening for hospitalized patients, the implementation of an evidence based guideline for clinical nutrition in the participating hospital, education training of the clinical staff and thereby optimal clinical nutrition for malnourished hospitalized patients.
Study NCT00673530 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: care as usual
Description: Unchanged treatment of hospital patients without interference by the study.
Study NCT02147561 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A
Description: Botulinum toxin Type A injected across specific head and neck muscles on Day 0.
Study NCT04721080 — intervention group
Intervention type: OTHER
Intervention: Functional Outcome Measurements
Description: Dyspnea Exercise capacity Quality of life assessment
Study NCT02829190 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI),
Description: Magnetic Resonance Imaging (MRI) of flow using phase contrast (PC) methods
Study NCT03835949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJ004309
Description: Antibody to CD73
Study NCT03835949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Humanized monoclonal antibody to PD-L1
Study NCT00775008 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: electronic health information
Description: Participants will receive weight loss information via 1 of 2 different mediums.
Study NCT00775008 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: electronic health information
Description: Participants will receive weight loss information via 1 of 2 different mediums.
Study NCT00616538 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epiceram(r)
Description: Topical barrier repair emulsion cream
Study NCT00616538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate 0.05%
Description: Topical mid-strength steroid
Study NCT04304638 — intervention group
Intervention type: RADIATION
Intervention: radiation or chemo-radiation
Description: standard treatment for stage III lung cancer
Study NCT04304638 — intervention group
Intervention type: DRUG
Intervention: EGFR-TKI Inhibitor
Description: the standard treatment for stage IV lung cancer with EGFR mutation
Study NCT01223742 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ACETYL-L-CARNITINE
Description: 2 g acetylcarnitine taken orally twice a day.
Study NCT01223742 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo twice per day
Study NCT01727024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Tiotropium via Respimat® device once a day
Study NCT01727024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol via Breezhaler® device once a day
Study NCT01852396 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retroclavicular block
Description: Retroclavicular approach ultrasound guided regional anesthesia
Study NCT00811096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinidazole
Description: 2gms, p.o. q.d. for 5 days
Study NCT00811096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chloroquine
Study NCT03294564 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Typhoid Vi Polysaccharide Vaccine
Description: Salmonella typhi capsular polysaccharide vaccine (Typhoid Vi Polysaccharide Vaccine): Each dose of 0.5ml Salmonella typhi capsular polysaccharide vaccine (Sanofi Pasteur, SA) is formulated to contain 25μg of purified Vi polysaccharide in a colorless isotonic phosphate buffered saline (pH 7±0.3), 4.150mg of sodium chloride, 0.065mg of disodium phosphate, 0.023mg of monosodium phosphate and 0.5ml of sterile water for injection. It is indicated for use by humans aged 2 years and older for protection against typhoid fever.
Study NCT03294564 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo injection will consist of 0.5mL of saline.
Study NCT02899572 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sexology consultation
Description: a sexology consultation is planned in the 15 days after inclusion
Study NCT00773539 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI using an open irrigated tip catheter
Description: transseptal PVI using thermocooled ablation catheter (Biosense) with confirmation of conduction block
Study NCT00773539 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI using a closed irrigated tip catheter
Description: transseptal PVI using the CHILLI II catheter from BOSTON with confirmation of conduction block
Study NCT00773539 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI using a cryoballoon
Description: transseptal PVI using the cryoballoon from CRYOCATH
Study NCT01600534 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle counseling
Description: Participants receive lifestyle counseling on healthy eating and physical activity through an internet-based program or self-directed educational program.
Study NCT01600534 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: lifestyle counseling
Description: Participants receive lifestyle counseling on healthy eating and physical activity through an internet-based program or self-directed educational program.
Study NCT01917253 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Device for peripheral vein cannulation
Study NCT01917253 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Long Catheters for peripheral vein cannulation
Study NCT00822549 — intervention group
Intervention type: DRUG
Intervention: intravenous morphine titration
Description: intravenous morphine titration
Study NCT02523144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloral Hydrate
Description: 70mg/kg chloral hydrate
Study NCT02523144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: 2mcg/kg
Study NCT02523144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: 3mcg/kg
Study NCT02523144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Flavored placebo syrup
Study NCT02567604 — intervention group
Intervention type: BEHAVIORAL
Intervention: Focus Groups
Description: at least three focus groups lasting approximately one hour
Study NCT02416622 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV2tYF-CB-hRS1
Description: adeno-associated virus vector expressing retinoschisin
Study NCT00498290 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: enhanced recovery after surgery (ERAS) protocol
Description: An integrated protocol aims to allow patients to recover more quickly from major surgery, avoid medium-term sequelae of conventional postoperative care (e.g. decline in nutritional status and fatigue) and reduce health care costs by reducing hospital stay
Study NCT00498290 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: control
Description: normal recovery protocol as usually
Study NCT04308967 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: balance exercises
Description: Three-stage progressive balance exercises will be applied.
Study NCT01776307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI608
Description: BBI608 is administered at 500 mg po bid continuously.
Study NCT01776307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab will be administered IV on day 8 and 22 of each 28 day cycle at 6 mg/kg over 60 minutes.
Study NCT01776307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will be administered orally at 1000 mg/m2 bid daily on days 8-21 every three weeks.
Study NCT01776307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be administered IV on day 5 at 400 mg/m2 intravenous infusion over 120 minutes as the initial dose, then weekly at 250mg/m2 over 60-minutes at subsequent cycles.
Study NCT01158170 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation
Description: 25GY/10fraction
Study NCT01158170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib /Gefitinib
Description: Erlotinib 150mg/d or Gefitinib 250mg/d until disease progression or intolerable toxicity
Study NCT01158170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib /Gefitinib
Description: Erlotinib 150mg/d or Gefitinib 250mg/d until disease progression or intolerable toxicity
Study NCT01105546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant activated factor VII
Description: 90 µg/kg/day i.v.
Study NCT01105546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant activated factor VII
Description: treatment of bleeding episodes with 270 µg/kg (first/single dose) or 90 µg/kg i.v. every 2-3 hours until bleeding resolution
Study NCT02499133 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: language and cognitive tests
Description: The participants will undergo seven different. The tests will include different cognitive and language examinations. The main test of the study will be The Hebrew Focused Stress Test (HFST). The HFST includes three subtests. The first subtest requires identification of the stressed word in a sentence based on psychoacoustic abilities alone. The second and the third subtests require understanding the meaning of focused stress in different contexts - lexical grammatical and pragmatic/social. The test includes forty eight recorded sentences. In each sentence one word is stressed. The participants will be asked to listen to the recordings and answer a closed question regarding the stressed word.
Study NCT04042090 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reducept, virtual reality
Description: The VR serious game Reducept is a novel psychological VR intervention for treating chronic pain. It incorporates several psychological therapies into one application: hypnotherapy, mindfulness, ACT and EMDR. Reducept has been made in co-creation with patients, researchers, psychologists and developers and can be installed and played on a VR goggles. It consists of an education module and three games.
Study NCT01835509 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention, Camp plus reunions
Study NCT01363349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYP-1020
Description: CYP-1020 (formerly known as BL-1020) is an orally available new chemical entity.
Study NCT01363349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Study NCT01958489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Description: Administered orally
Study NCT01958489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: Administered orally
Study NCT01717833 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NEMS
Description: NEMS sessions on both lower extremities (quadriceps and peroneus longus) simultaneously
Study NCT01717833 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham sessions of neuromuscular electrical stimulation
Study NCT00573144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nesiritide
Description: Infusion of 72 hours of IV nesiritide at 0.006 mcg/kg/min.
Study NCT00573144 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Infusion of 72 hours of saline solution (packaged to match active comparator)
Study NCT03569345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFXl-assisted ingenol mebutate delivery
Description: Patients will receive ablative fractional laser (AFXl)-assisted ingenol mebutate (IM) as a treatment for their cutaneous basal cell carcinoma (BCC). Treatment areas consisting of tumors and a 5 mm margin will undergo AFXl exposure (CO2 laser) followed by IM 0.015% or 0.05% under occlusion for 2-3 days. .~local skin reactions are monitored at baseline (day1), day 3/4, day 8, day 15, day 29, day 90, and tumor response monitored at baseline, day 29, and day 90. An additional repeat AFXl-IM treatment on day 29 will be offered if tumors persist, based on clinical evaluation and imaging on day 30.
Study NCT00644007 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo as a substitute of SK3530 100mg
Study NCT00644007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SK3530
Description: SK3530 100 mg
Study NCT01529138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Combination treatment with temsirolimus and axitinib
Study NCT01529138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Combination treatment with temsirolimus and axitinib
Study NCT01087736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: After random assignment, topiramate will be titrated up over 5 weeks. Dosing begins at 25 mg per day, and increase in the second week to 25 mg twice per day; in the third week to 50 mg twice/day; in the fourth week to 75 mg twice/day; in the 5th week to 100 mg twice/day; and in weeks 6-11 increased to and maintained at 100 mg in the morning and 200 mg at night. Patients will receive the highest dose tolerated, not to exceed 300 mg per day. Adjustments are permitted throughout titration. Once maximum tolerated dosage is reached, subjects will be asked to maintain dosage for remainder of the treatment phase. Upon completing the 6 week maintenance period subjects will taper off over a 7-day period (Week 12). If subjects experience significant side effects, the dosage may be adjusted.
Study NCT01087736 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo administration
Description: Placebo pills will be prepared by the UCSF pharmacy which will be indistinguishable from the topiramate pills used in that arm. Both topiramate and placebo will then be delivered to the VA pharmacy. A consulting biostatistician will randomly assign participants to either the topiramate or placebo group. The dosing of placebo pills will follow the same regimen as outlined for the topiramate arm. In the event of a safety issue, there will be a procedure for unblinding only that participant.
Study NCT02120040 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: evaluation of anxiety with psychosocial scales
Study NCT02780011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Antibody-drug conjugate composed of the anti-CD30 chimeric immunoglobulin G1 monoclonal antibody cAC10 and the antimicrotubule drug monomethyl auristatin E connected by a protease-cleavable linker.
Study NCT02780011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alsertib
Description: Aurora A kinase inhibitor
Study NCT02238067 — intervention group
Intervention type: DRUG
Intervention: ESA
Description: Participants will continue to receive their ESA treatment, as per physician's discretion. The study protocol does not specify any particular ESA drug.
Study NCT02238067 — intervention group
Intervention type: OTHER
Intervention: Satisfaction Survey Questionnaire
Description: Each participant will be interviewed to complete treatment satisfaction questionnaire survey at baseline and at 6-month follow-up visit.
Study NCT03083990 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI305(Bevacizumab Biosimilar)
Description: 3mg/kg, infusion in 90minutes
Study NCT03083990 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin(Bevacizumab)
Description: 3mg/kg, infusion in 90minutes
Study NCT01430442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimegepant
Description: Rimegepant capsules
Study NCT01430442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Rimegepant placebo-matching capsules
Study NCT01430442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Rimegepant placebo-matching capsules
Study NCT01430442 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Rimegepant placebo-matching capsules
Study NCT01430442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan
Description: Rimegepant matching sumatriptan and Rimegepant matching placebo capsules